Status:
COMPLETED
AZD7325 Multiple Ascending Dose Study
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Volunteer
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD7325 after single and repeated ascending doses.
Eligibility Criteria
Inclusion
- Female subjects must be of non-child bearing potential.
Exclusion
- Clinically significant illness within 2 weeks before the study start.
- Enrollment in another concurrent investigational study or intake of an investigational drug within 30 days or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit
- Blood loss in excess of 200 mL within 30 days of Day -2, in excess of 400 mL within 90 days of Day -2, or in excess of 1200 mL within 1 year of Day -2
- Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2008
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00681915
Start Date
March 1 2008
End Date
July 1 2008
Last Update
December 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Philadelphia, Pennsylvania, United States